KIFFIK Biomedical Onboards Industry Leaders Rene Veloso and Dr. Reginald Swift to Expand Business and Clinical Operations
RIO
-0.3300
The Fort Worth Press - KIFFIK Biomedical Onboards Industry Leaders Rene Veloso and Dr. Reginald Swift to Expand Business and Clinical Operations
USD
-
AED 3.672498
AFN 64.999682
ALL 81.827235
AMD 365.160186
ANG 1.789785
AOA 917.999742
ARS 1544.481598
AUD 1.46107
AWG 1.8
AZN 1.706428
BAM 1.762379
BBD 2.036128
BDT 126.028385
BGN 1.747831
BHD 0.381383
BIF 3024.210446
BMD 1
BND 1.292395
BOB 11.989636
BRL 5.583699
BSD 1.010945
BTN 95.007435
BWP 13.869176
BYN 3.0269
BYR 19600
BZD 2.033164
CAD 1.426105
CDF 2314.999732
CHF 0.833275
CLF 0.024992
CLP 983.609895
CNY 6.67035
CNH 6.66699
COP 3280.9
CRC 457.263359
CUC 1
CUP 24.260419
CVE 99.36917
CZK 22.02055
DJF 180.019916
DKK 6.750195
DOP 61.316908
DZD 136.897983
EGP 53.547704
ERN 15
ETB 164.541452
EUR 0.902992
FJD 2.26815
FKP 0.753031
GBP 0.754375
GEL 2.598309
GGP 0.753031
GHS 11.838234
GIP 0.753031
GMD 73.999988
GNF 8956.017465
GTQ 7.724958
GYD 211.837332
HKD 7.84405
HNL 27.174457
HRK 6.76901
HTG 132.510848
HUF 329.413982
IDR 18235.95
ILS 3.174849
IMP 0.753031
INR 93.831985
IQD 1532.417211
IRR 1906074.999698
ISK 123.350474
JEP 0.753031
JMD 160.446988
JOD 0.708962
JPY 159.782495
KES 129.960042
KGS 87.449603
KHR 4122.94022
KMF 442.000317
KPW 899.999961
KRW 1332.774996
KWD 0.31137
KYD 0.842352
KZT 451.299842
LAK 22755.230323
LBP 90528.995629
LKR 335.972315
LRD 171.855991
LSL 16.573648
LTL 2.95274
LVL 0.60489
LYD 6.480393
MAD 9.86162
MDL 18.166334
MGA 4574.394744
MKD 55.575371
MMK 2099.724407
MNT 3604.903758
MOP 8.167515
MRU 40.781511
MUR 47.169835
MVR 15.399797
MWK 1752.977277
MXN 18.605976
MYR 4.081897
MZN 63.89969
NAD 16.571931
NGN 1345.740046
NIO 37.201087
NOK 9.569402
NPR 152.012581
NZD 1.797825
OMR 0.384506
PAB 1.010972
PEN 3.44501
PGK 4.540191
PHP 63.663007
PKR 277.574021
PLN 3.983398
PYG 6240.678409
QAR 3.685126
RON 4.827105
RSD 106.191869
RUB 83.07543
RWF 1495.696841
SAR 3.772213
SBD 8.090747
SCR 13.937946
SDG 601.50203
SEK 9.985755
SGD 1.285215
SHP 0.749316
SLE 22.902058
SLL 20969.504398
SOS 577.749741
SRD 37.645974
STD 20697.981008
STN 22.079133
SVC 8.845235
SYP 13001.999685
SZL 16.578126
THB 33.783503
TJS 9.290497
TMT 3.5
TND 3.012932
TOP 2.40776
TRY 50.261103
TTD 6.855598
TWD 32.930497
TZS 2658.158982
UAH 45.980237
UGX 4124.816943
UYU 40.90479
UZS 12104.528047
VES 900.490495
VND 25682
VUV 119.943861
WST 2.787799
XAF 592.324219
XAG 0.019376
XAU 0.000251092251
XCD 2.70255
XCG 1.821762
XDR 0.707052
XOF 592.324219
XPF 107.465645
YER 236.503327
ZAR 16.6022
ZMK 9001.199211
ZMW 20.597486
ZWL 321.999592
SSP 5786.523514
MXV 2.090565
- Mexico's Journalist Protection Mechanism Fails Under Scrutiny Amid Rising Threats
- Sister recounts fatal machete attack as Irish murder trial continues
- Georgia refrigeration company sues EPA after five-year HFC reprieve
- HoloCoder technology promises brighter smartphone images and 3D depth data
- EU proposes broad consumer safeguards for apps, subscriptions and ticketing
- Early Black Friday Walking Pad Deals: Urevo and WalkingPad Discounts
- Nvidia faces scrutiny over alleged Chinese intelligence link to Jensen Huang
- Radical Numerics develops offline AI tool to detect engineered pathogens
- Chennai orders inquiry after dogs die at shelter; two veterinarians face action
- Startup turns Chennai’s history and culture into an interactive world
KIFFIK Biomedical Onboards Industry Leaders Rene Veloso and Dr. Reginald Swift to Expand Business and Clinical Operations
Rene Veloso, JD, MBA, joins KIFFIK to lead investor relations and secure new funding to fuel clinical operations
Rubix Life Sciences CEO Reginald Swift, Ph.D. joins as Chief Scientific Officer with responsibility to shape KIFFIK's clinical strategy
PROVIDENCE, RI / ACCESS Newswire / August 13, 2025 / KIFFIK Biomedical, Inc. ("Kiffik"), a leader in interstitial fluid (ISF)-based diagnostics, today announced two new appointments to its leadership team. Healthcare development executive Rene Veloso joins as Chief Investment Officer (CIO) along with Dr. Reginald(Reggie) Swift who will serve as a fractional Chief Scientific Officer (CSO).
"The addition of Rene and Reggie to our already strong leadership team is a game-changer as we embark on our next chapter of growth," said George Cagna, CEO of KIFFIK Biomedical. "Ensuring our R&D function is meeting the highest scientific standards, coupled with securing operating capital, empowers our team to bring next-generation ISF biomonitoring to partners and patients."
As CIO, Rene will be responsible for securing capital investments from institutional partners that want to unlock the full potential of interstitial fluid real-time monitoring for a range of cancers and other diseases. Most recently, Rene was Senior Vice President at Locust Walk Partners, LLC where he led multiple high-profile M&A activities on behalf of biopharma clients.
Dr. Reginald Swift is the CEO of Rubix Life Sciences, a leader in aptamer-based precision medicine. As a fractional CSO for KIFFIK Dr. Swift will help shape clinical operations to ensure research and development activities meet the highest scientific standards. Earlier this year, KIFFIK and Rubix LS established a strategic partnership to advance next-generation ISF extraction technology.
About KIFFIK Biomedical
KIFFIK Biomedical is pioneering interstitial fluid (ISF)-based diagnostics, transforming disease detection and health monitoring with a needle-free, real-time approach. As a leader in ISF science and biomarker detection, we are redefining non-invasive diagnostics for oncology, therapeutic monitoring, and beyond.
Our proprietary and patented KIFFIK EXP platform unlocks the potential of ISF, providing high-precision, accessible, and patient-friendly solutions. Through strategic partnerships and cutting-edge research, KIFFIK is driving the future of precision medicine and advancing diagnostics that empower earlier detection and better health outcomes.
###
Media Contact
MDL Strategic Communications
Michael Lauer
[email protected]
SOURCE: Kiffik
View the original press release on ACCESS Newswire
C.Dean--TFWP
